Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL. Dreyling M, et al. Among authors: mollica l. Am J Hematol. 2020 Apr;95(4):362-371. doi: 10.1002/ajh.25711. Epub 2020 Jan 16. Am J Hematol. 2020. PMID: 31868245 Free article.
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL. Dreyling M, et al. Among authors: mollica l. J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4. J Clin Oncol. 2017. PMID: 28976790 Clinical Trial.
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Quebec CML Group. Klil-Drori AJ, et al. Among authors: mollica l. Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29. Am J Hematol. 2017. PMID: 28670773 Free article. No abstract available.
Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
Lemieux C, Ahmad I, Bambace NM, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Roy J, Lachance S. Lemieux C, et al. Among authors: mollica l. Biol Blood Marrow Transplant. 2020 Jan;26(1):157-161. doi: 10.1016/j.bbmt.2019.09.007. Epub 2019 Sep 12. Biol Blood Marrow Transplant. 2020. PMID: 31521818 Free article. Clinical Trial.
Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective.
Veilleux O, Claveau JS, Alaoui H, Roy J, Ahmad I, Delisle JS, Kiss T, Bambace NM, Bernard L, Cohen S, Sauvageau G, Fleury I, Mollica L, Roy DC, Serroukh Y, Lachance S. Veilleux O, et al. Among authors: mollica l. Transplant Cell Ther. 2022 Mar;28(3):145-151. doi: 10.1016/j.jtct.2021.12.005. Epub 2021 Dec 23. Transplant Cell Ther. 2022. PMID: 34954149 Free article.
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.
Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP). Klil-Drori AJ, et al. Among authors: mollica l. Cancer. 2019 Feb 15;125(4):618-625. doi: 10.1002/cncr.31835. Epub 2018 Nov 13. Cancer. 2019. PMID: 30423211 Free article.
Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy.
Liu J, Stewart D, Fontaine A, Peters A, Fleury I, Mollica L, Prica A, Buckstein R, Sehn L, Jiang A, Kuruvilla J, Villa D. Liu J, et al. Among authors: mollica l. Leuk Lymphoma. 2020 Oct;61(10):2492-2496. doi: 10.1080/10428194.2020.1772472. Epub 2020 Jun 10. Leuk Lymphoma. 2020. PMID: 32519592 No abstract available.
94 results